Esperion monetizes European bempedoic acid royalties for $304.7M, pays off Oberland facility

Esperion Therapeutics, Inc.

Received $304.7M from OMERS in exchange for 100% of European bempedoic acid royalty until OMERS receives 1.7x investment (≈$518M), then royalties revert to Esperion.
Used proceeds to early payoff and termination of Oberland Capital revenue interest facility for $343.75M cash, removing senior secured liens.
Esperion retains potential future commercial milestones from DSE of up to $300M based on net sales thresholds.
Royalty to OMERS is tiered 15-25% of DSE net sales; Esperion regains full royalty stream after cap is reached.
CFO Ben Halladay cited enhanced balance sheet and increased operational flexibility to focus on U.S. commercialization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.